KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Free Cash Flow (2016 - 2025)

Gilead Sciences (GILD) has disclosed Free Cash Flow for 17 consecutive years, with $3.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 10.4% year-over-year to $3.1 billion, compared with a TTM value of $9.5 billion through Dec 2025, down 8.24%, and an annual FY2025 reading of $9.5 billion, down 8.24% over the prior year.
  • Free Cash Flow was $3.1 billion for Q4 2025 at Gilead Sciences, down from $4.0 billion in the prior quarter.
  • Across five years, Free Cash Flow topped out at $4.2 billion in Q3 2024 and bottomed at $720.0 million in Q2 2025.
  • Average Free Cash Flow over 5 years is $2.3 billion, with a median of $2.2 billion recorded in 2021.
  • Peak annual rise in Free Cash Flow hit 155.24% in 2024, while the deepest fall reached 45.66% in 2024.
  • Year by year, Free Cash Flow stood at $3.0 billion in 2021, then decreased by 21.74% to $2.4 billion in 2022, then fell by 18.11% to $2.0 billion in 2023, then skyrocketed by 44.73% to $2.8 billion in 2024, then increased by 10.4% to $3.1 billion in 2025.
  • Business Quant data shows Free Cash Flow for GILD at $3.1 billion in Q4 2025, $4.0 billion in Q3 2025, and $720.0 million in Q2 2025.